Trending...
- Federal indictments bring new scrutiny to SPLC practices and highlight the real‑world impact of its designations on nonprofit groups, including NCFM
- Kaltra Expands Microchannel Water Coil Line for U.S. HVAC Market With New Corrosion-Resistant Tube Technology
- Could You Make a 2026 World Cup Squad? A New Free Tool Will Tell You Where You'd Sit on Any National Team's Bench in 90 Seconds
Download
Photo courtesy of Labcorp
BURLINGTON, N.C.--(BUSINESS WIRE)--Nearly 10 million people in the United States have a history of systemic or anaphylactic reaction to insect stings, with the risk of a severe and potentially life-threatening allergic reaction. To help facilitate more effective venom therapy, Labcorp (NYSE: LH), a leading global life sciences company, has launched its unique Labcorp Clinical Decision Support (CDS) interpretative test report for its Stinging Insect Component-Specific IgE Test that provides allergen test interpretation and treatment suggestions.
More on ncarol.com
"Labcorp is the only reference laboratory to offer stinging insect (venom) component testing," said Dr. Andre Valcour, vice president and laboratory director of Labcorp Diagnostic's esoteric testing unit. "The launch of this new interpretative report is another example of how Labcorp continues to provide clinical expertise and value to providers and patients by identifying specific insect species for therapy and offering guidance on successful venom immunotherapy."
Over half of stinging insect patients test positive for allergic reactions to both honeybee and yellow jacket (wasp) venom. Labcorp's Stinging Insect Component-Specific IgE Testing helps identify the specific venom to which the patient is allergic and provides a more precise diagnosis to support venom immunotherapy. Venom-specific immunotherapy (VIT) is an effective treatment for venom allergy that can help protect against future reactions, minimize side effects and lower treatment costs.
The Labcorp CDS interpretative venom allergy report expands on prior reporting to provide report interpretation and uses current Allergy Practice Parameters, which are sponsored by the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology, to offer treatment suggestions. Dr. David Golden, a leading expert on stinging insect allergies and former chair of the Stinging Insect Hypersensitivity Practice Parameter Update workgroup, collaborated with Labcorp to establish this vital report.
"It is very important to identify the specific insect species for effective therapy," said Dr. Golden, an associate professor of medicine at Johns Hopkins University and the allergy division chief at both Sinai Hospital and Franklin Square Hospital in Baltimore, Maryland. "Venom component testing is valuable as it can differentiate between species-specific sensitization and cross-reactivity, fine tune venom diagnosis, and help physicians determine the most appropriate and cost-effective treatment plans for patients."
The Labcorp CDS interpretive report follows the Practice Parameters and provides physicians comprehensive insight on diagnostic marker interpretation, treatment suggestions and guidance for managing venom and stinging insect therapy. To learn about the Practice Parameters, visit their website.
More on ncarol.com
About Labcorp
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With over 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $16 billion in FY2021. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.
Contacts
Labcorp Contacts:
Media: Christopher Allman-Bradshaw – 336-436-8263
Media@Labcorp.com
Investors: Chas Cook – 336-436-5076
Investor@Labcorp.com
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
Contacts
Labcorp Contacts:
Media: Christopher Allman-Bradshaw – 336-436-8263
Media@Labcorp.com
Investors: Chas Cook – 336-436-5076
Investor@Labcorp.com
Photo courtesy of Labcorp
BURLINGTON, N.C.--(BUSINESS WIRE)--Nearly 10 million people in the United States have a history of systemic or anaphylactic reaction to insect stings, with the risk of a severe and potentially life-threatening allergic reaction. To help facilitate more effective venom therapy, Labcorp (NYSE: LH), a leading global life sciences company, has launched its unique Labcorp Clinical Decision Support (CDS) interpretative test report for its Stinging Insect Component-Specific IgE Test that provides allergen test interpretation and treatment suggestions.
More on ncarol.com
- American Properties Celebrates Grand Opening and Ribbon Cutting Ceremony at Heritage at South
- Crosswalk Ministries USA Announces 2026 Child and Family Well-Being Conference in Stockbridge, Georgia
- Research reveals "The Borderless Pay Standard," a 48-point gap between multinational employers and workers on transparent pay expectations
- Global.ai Appoints Freedomtech Solutions as Specialist Partner for Agentic AI
- ASCLD Honors Jeremy Triplett with 2026 Briggs J. White Award
"Labcorp is the only reference laboratory to offer stinging insect (venom) component testing," said Dr. Andre Valcour, vice president and laboratory director of Labcorp Diagnostic's esoteric testing unit. "The launch of this new interpretative report is another example of how Labcorp continues to provide clinical expertise and value to providers and patients by identifying specific insect species for therapy and offering guidance on successful venom immunotherapy."
Over half of stinging insect patients test positive for allergic reactions to both honeybee and yellow jacket (wasp) venom. Labcorp's Stinging Insect Component-Specific IgE Testing helps identify the specific venom to which the patient is allergic and provides a more precise diagnosis to support venom immunotherapy. Venom-specific immunotherapy (VIT) is an effective treatment for venom allergy that can help protect against future reactions, minimize side effects and lower treatment costs.
The Labcorp CDS interpretative venom allergy report expands on prior reporting to provide report interpretation and uses current Allergy Practice Parameters, which are sponsored by the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology, to offer treatment suggestions. Dr. David Golden, a leading expert on stinging insect allergies and former chair of the Stinging Insect Hypersensitivity Practice Parameter Update workgroup, collaborated with Labcorp to establish this vital report.
"It is very important to identify the specific insect species for effective therapy," said Dr. Golden, an associate professor of medicine at Johns Hopkins University and the allergy division chief at both Sinai Hospital and Franklin Square Hospital in Baltimore, Maryland. "Venom component testing is valuable as it can differentiate between species-specific sensitization and cross-reactivity, fine tune venom diagnosis, and help physicians determine the most appropriate and cost-effective treatment plans for patients."
The Labcorp CDS interpretive report follows the Practice Parameters and provides physicians comprehensive insight on diagnostic marker interpretation, treatment suggestions and guidance for managing venom and stinging insect therapy. To learn about the Practice Parameters, visit their website.
More on ncarol.com
- BarnOps Launches Equine Facility Management Software with GPS Staff Tracking and Weather Alerts
- Lansdowne Photographer Steven Weisz Selected for Philadelphia City Hall Exhibition
- Federal indictments bring new scrutiny to SPLC practices and highlight the real‑world impact of its designations on nonprofit groups, including NCFM
- Shedrack Anderson Releases New Album
- Could You Make a 2026 World Cup Squad? A New Free Tool Will Tell You Where You'd Sit on Any National Team's Bench in 90 Seconds
About Labcorp
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With over 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $16 billion in FY2021. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.
Contacts
Labcorp Contacts:
Media: Christopher Allman-Bradshaw – 336-436-8263
Media@Labcorp.com
Investors: Chas Cook – 336-436-5076
Investor@Labcorp.com
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
Contacts
Labcorp Contacts:
Media: Christopher Allman-Bradshaw – 336-436-8263
Media@Labcorp.com
Investors: Chas Cook – 336-436-5076
Investor@Labcorp.com
0 Comments
Latest on ncarol.com
- AI-Driven Defense Expansion, Autonomous Systems and Israeli Aerospace Manufacturing Platform: VisionWave Holdings (N A S D A Q: VWAV)
- AI Predicts the Most Likely 2026 FIFA World Cup Winner
- The AI Production Shift: Why Game Development Is Entering Its Most Accelerated Phase
- World-First AI Humanoid Robot Debuts on Cherie Barber's Ground-breaking Australian Reno Show
- New Survey Reveals America's Most Feared Bridges for Cyclists — Golden Gate Tops the List
- Raymond Lavine, Extended Care Benefits Advisor and Author, to Appear on National Television Series Moving America Forward
- NaturismRE Launches Structured Nudism & Naturism Encyclopedia, Aiming to Reframe Public Understanding
- AI Is Closing the Gap Between Offshore Virtual Assistants and Onshore Staff
- CCHR Highlights Concerns Over Coercive and Failed $140 Billion Mental Health Practices at Psychiatric Convention
- Avery Headley Leads Major Stabilization and Modernization Initiative Across Bronx Affordable Housing Portfolio
- America's Boating Channel® Releases New Video Explaining Give-Way and Stand-On Vessel Navigation Rules
- NewReputation's AI Sentiment Analysis Tool Reaches 2,500 Users as Businesses Demand Clearer Brand Intelligence
- Sunday Best Winner Tasha Page-Lockhart Headlines A'Leurer's 1-Year Anniversary Celebration in Greensboro
- CAPO Supply Announces Opening of Second Location in New Castle, Pennsylvania
- $224 Billion Growing Market in Life Settlements Presents Major Opportunity for New Policy Acquisition Business Plan: DLT Resolution Stock Symbol: DLTI
- New from Regal House Publishing, Margery and Me, based on the true story of psychic Margery Crandon
- Fyt-02 Launches on Kickstarter The Smart Sensor That Turns Any Chair Into a Posture & Movement Track
- YieldOMega Launches $DOUB Airdrop Campaign Ahead of TimeCurve Launch
- Kaltra Expands Microchannel Water Coil Line for U.S. HVAC Market With New Corrosion-Resistant Tube Technology
- Collectibles EvoRelic Celebrates Stellar 4.8-Star Customer Rating